The Cannabis Metabolomics Experiment Defined Attention Lapses With a 500-Millisecond Threshold
The metabolomics experiment’s principal performance outcome was the number of slow responses on a six-minute vigilance task. It was not a direct measurement of every cognitive function or driving performance.
The endpoint was operationally defined
Participants responded to visual stimuli in a psychomotor vigilance task. Responses exceeding 500 milliseconds counted as attentional lapses. This definition creates a consistent outcome for comparing cannabis and placebo conditions. It does not mean that 500 milliseconds is a universal clinical or legal boundary for cannabis impairment.
One task cannot directly establish every domain
The authors selected a sensitive attention measure and discussed a shared neural rationale for broader THC effects. That rationale does not substitute for measuring memory, complex decision making, divided attention or on-road behavior within this experiment. Associations with the lapse outcome should retain the actual task name and definition.
The observation period was also bounded
Testing occurred early after vaporization, at ten and thirty minutes. The resulting associations do not map the full onset and recovery trajectory. A blood marker related to lapses at those assessments would still need validation against other tasks, time points and exposures. The study provides a specific functional anchor for metabolomic research, rather than an established all-purpose impairment score.
Related analysis: the study’s broader findings and limitations.
